Evidence map›Paper›PMID 23718152›Full record

Trial reportThe New England journal of medicine2013

Targeted versus universal decolonization to prevent ICU infection.

Susan S Huang, Edward Septimus, Ken Kleinman, Julia Moody, Jason Hickok, Taliser R Avery, Julie Lankiewicz, Adrijana Gombosev, Leah Terpstra, Fallon Hartford and 12 more

Erratum issued 2 registry-linked trialsAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 314 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
314citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00980980 nacompletednot on this map

Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal

TypeinterventionalSponsorHarvard Pilgrim Health CareRan2009 to 2011Enrolled74,256ConditionsMethicillin-resistant Staphylococcus AureusArmsChlorhexidine bath and nasal mupirocin
NCT03268122 nacompletednot on this mapstarted 2017, after this paper: background citation

Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE: A Pilot Clinical Trial

TypeinterventionalSponsorVanderbilt University Medical CenterRan2017 to 2018Enrolled1,974ConditionsMRSA, VRE InfectionArmsStandard Contact Isolation, Targeted Contact Isolation
3 · Its place in the literature

Who cites it

314 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Mupirocin forPediatrics · 2019
    Trial
  19. Trial
  20. Trial

254 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Susan S HuangUniversity of California Irvine School of Medicine, Orange, CA 92868, USA. sshuang@uci.edu
Edward Septimus
Ken Kleinman
Julia Moody
Jason Hickok
Taliser R Avery
Julie Lankiewicz
Adrijana Gombosev
Leah Terpstra
Fallon Hartford
Mary K Hayden
John A Jernigan
Robert A Weinstein
Victoria J Fraser
Katherine Haffenreffer
Eric Cui
Rebecca E Kaganov
Karen Lolans
Jonathan B Perlin
Richard Platt
CDC Prevention Epicenters Program
AHRQ DECIDE Network and Healthcare-Associated Infections Program

Funding

Eastern Massachusetts Prevention Epicenters Program IIU01CI000344 · CI · HARVARD PILGRIM HEALTH CARE, INC. · PI PLATT, RICHARD · 2006 to 2010
$1.8M
Intramural CDC HHS CC999999Medical Research Council G1000803NCPDCID CDC HHS 1U01 CI000344NCPDCID CDC HHS U01 CI000344
6 · The paper itself

Abstract

backgroundBoth targeted decolonization and universal decolonization of patients in intensive care units (ICUs) are candidate strategies to prevent health care-associated infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA).

methodsWe conducted a pragmatic, cluster-randomized trial. Hospitals were randomly assigned to one of three strategies, with all adult ICUs in a given hospital assigned to the same strategy. Group 1 implemented MRSA screening and isolation; group 2, targeted decolonization (i.e., screening, isolation, and decolonization of MRSA carriers); and group 3, universal decolonization (i.e., no screening, and decolonization of all patients). Proportional-hazards models were used to assess differences in infection reductions across the study groups, with clustering according to hospital.

resultsA total of 43 hospitals (including 74 ICUs and 74,256 patients during the intervention period) underwent randomization. In the intervention period versus the baseline period, modeled hazard ratios for MRSA clinical isolates were 0.92 for screening and isolation (crude rate, 3.2 vs. 3.4 isolates per 1000 days), 0.75 for targeted decolonization (3.2 vs. 4.3 isolates per 1000 days), and 0.63 for universal decolonization (2.1 vs. 3.4 isolates per 1000 days) (P=0.01 for test of all groups being equal). In the intervention versus baseline periods, hazard ratios for bloodstream infection with any pathogen in the three groups were 0.99 (crude rate, 4.1 vs. 4.2 infections per 1000 days), 0.78 (3.7 vs. 4.8 infections per 1000 days), and 0.56 (3.6 vs. 6.1 infections per 1000 days), respectively (P<0.001 for test of all groups being equal). Universal decolonization resulted in a significantly greater reduction in the rate of all bloodstream infections than either targeted decolonization or screening and isolation. One bloodstream infection was prevented per 54 patients who underwent decolonization. The reductions in rates of MRSA bloodstream infection were similar to those of all bloodstream infections, but the difference was not significant. Adverse events, which occurred in 7 patients, were mild and related to chlorhexidine.

conclusionsIn routine ICU practice, universal decolonization was more effective than targeted decolonization or screening and isolation in reducing rates of MRSA clinical isolates and bloodstream infection from any pathogen. (Funded by the Agency for Healthcare Research and the Centers for Disease Control and Prevention; REDUCE MRSA ClinicalTrials.gov number, NCT00980980).

Indexed as

Intensive Care UnitsMethicillin-Resistant Staphylococcus aureusAdultAgedBacteremiaBathsCarrier StateChlorhexidineComparative Effectiveness ResearchCross InfectionDisease Transmission, InfectiousDisinfectionFemaleHumansInfection ControlMaleChlorhexidineMupirocin

Identifiers

PMID23718152
PMCPMC10853913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.